Research last month suggested that starting GLP-1 receptor agonist treatment in people with epilepsy and type 2 diabetes was ...

As people with type 1 diabetes live longer than ever before, both clinicians and patients are recognizing the need to prepare ...

For almost two-thirds of his life, Nick Jonas has lived with a chronic condition — type 1 diabetes. The Jonas Brothers-famed ...

AIIMS Delhi reports metabolic surgery helps many with uncontrolled Type-2 diabetes; 30% stopped meds. Early intervention ...

Patients with T2D taking incretin-based drugs do not face an increased risk for pancreatitis but have a modestly higher risk ...

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

Diabetes insipidus can lead to severe dehydration. It is essential to recognize the main symptoms of diabetes insipidus and understand the main causes, as well as diagnostic and treatment methods to ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Experts say neither diet soda nor zero-sugar soda raises blood sugar directly, but knowing the differences between them—and ...

China NMPA approves Sanofi’s Qfitlia for haemophilia and Cablivi for acquired thrombotic thrombocytopenic purpura: Paris Friday, December 12, 2025, 09:00 Hrs [IST] The National ...

Most Medicare beneficiaries reported manageable treatment burdens from health care. Among Medicare beneficiaries with heavier chronic condition burdens, 1 in 4 Medicare Advantage enrollees faced high ...

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...